Description
ROSUROOT-F
Rosuvastatin 20 mg and Fenofibrate 160 mg Tablets
Division: DIABGLYM
Composition
Each film-coated tablet contains:
Rosuvastatin Calcium IP equivalent to Rosuvastatin — 20 mg
Fenofibrate IP — 160 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Film-coated oral tablet
Product Description
ROSUROOT-F is a comprehensive lipid-lowering combination containing Rosuvastatin 20 mg and Fenofibrate 160 mg, formulated for the effective management of mixed dyslipidemia, diabetic dyslipidemia, hypertriglyceridemia, and patients with elevated LDL cholesterol and triglyceride levels. This combination provides dual lipid-modifying action by significantly reducing LDL cholesterol, triglycerides, VLDL cholesterol, and non-HDL cholesterol while improving HDL cholesterol levels.
Rosuvastatin is a potent HMG-CoA reductase inhibitor that effectively lowers LDL cholesterol and reduces cardiovascular risk, while Fenofibrate is a fibric acid derivative that primarily reduces triglycerides and improves atherogenic lipid abnormalities. Together, they provide superior lipid control in high-risk patients with diabetes, metabolic syndrome, obesity, cardiovascular disease, and mixed dyslipidemia.
ROSUROOT-F is particularly beneficial in patients with diabetic dyslipidemia where elevated triglycerides and low HDL cholesterol coexist with increased LDL cholesterol, a pattern strongly associated with accelerated atherosclerosis and cardiovascular complications.
Technical Knowledge of Rosuvastatin and Fenofibrate
Rosuvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in hepatic cholesterol biosynthesis, leading to increased LDL receptor expression and enhanced clearance of circulating LDL cholesterol. It also reduces VLDL production and provides anti-inflammatory and plaque-stabilizing effects.
Fenofibrate activates Peroxisome Proliferator-Activated Receptor Alpha (PPAR-α), resulting in increased lipoprotein lipase activity, enhanced triglyceride-rich lipoprotein clearance, reduced hepatic VLDL synthesis, increased HDL production, and improved lipid metabolism.
The combination of Rosuvastatin and Fenofibrate offers complementary mechanisms that target both cholesterol and triglyceride abnormalities, providing comprehensive lipid management in high cardiovascular risk patients.
Mechanism of Action
Rosuvastatin reduces hepatic cholesterol synthesis, increases LDL receptor activity, lowers LDL cholesterol and total cholesterol, decreases VLDL production, and stabilizes atherosclerotic plaques.
Fenofibrate activates PPAR-α receptors, enhances lipoprotein lipase activity, reduces triglycerides and VLDL, increases HDL cholesterol, and improves overall lipid metabolism.
Key Benefits
Powerful reduction of LDL cholesterol
Significant triglyceride lowering
Improves HDL cholesterol levels
Reduces non-HDL cholesterol
Comprehensive management of mixed dyslipidemia
Beneficial in diabetic dyslipidemia
Supports cardiovascular risk reduction
Helps improve atherogenic lipid abnormalities
Suitable for long-term lipid management under medical supervision
Clinical Applications
ROSUROOT-F is commonly prescribed for mixed dyslipidemia, diabetic dyslipidemia, hypertriglyceridemia, combined hyperlipidemia, metabolic syndrome, cardiovascular risk reduction, atherosclerotic cardiovascular disease prevention, and patients with elevated LDL cholesterol and triglycerides.
Facts About Rosuvastatin and Fenofibrate
Rosuvastatin is one of the most potent statins available for LDL cholesterol reduction and has extensive evidence supporting cardiovascular risk reduction. Fenofibrate is particularly effective in reducing triglycerides and increasing HDL cholesterol. The combination is especially useful in diabetic patients with mixed dyslipidemia and elevated triglycerides, where comprehensive lipid control is essential for reducing residual cardiovascular risk.
Key Facts
Dual lipid-lowering combination therapy
Rosuvastatin 20 mg for intensive LDL reduction
Fenofibrate 160 mg for triglyceride control
Effective in diabetic and mixed dyslipidemia
Supports cardiovascular and metabolic risk reduction
Evidence-based combination therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
ROSUROOT-F is an excellent product for PCD Pharma Franchise, Cardio-Diabetic Franchise, and Lipid Management Franchise across India. The rapidly increasing prevalence of diabetes, dyslipidemia, obesity, metabolic syndrome, and cardiovascular disease creates strong prescription demand and long-term market potential for this combination.
Why Choose ROSUROOT-F for PCD Pharma Franchise?
High prescription potential
Strong physician, cardiologist, and diabetologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Rosuvastatin and Fenofibrate Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented formulation
Moisture-controlled tablet manufacturing
Blister and Alu-Alu packaging options
ROSUROOT-F from DIABGLYM combines intensive LDL cholesterol reduction, effective triglyceride control, comprehensive cardiovascular protection, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, diabetologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable and evidence-based lipid-lowering combination.